Vaccination is the most cost-effective public health intervention for the control and eradication of infectious diseases, including the coronavirus disease 2019 (COVID-19). Ensuring equitable access to all vaccines is needed, particularly now with the significant global demand for vaccine doses to contain the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the focus on ensuring the availability of COVID-19 vaccines has affected the manufacturing and supply chain of other vaccines. In addition, the COVID-19 pandemic has resulted in a drop in health service use including immunization services.1 This drop will likely lead to an increase in the risk of vaccine-preventable infectious disease outbreaks.2 The support from Gavi, the Vaccine Alliance and other global donors through COVAX has been instrumental in providing SARS-CoV-2 vaccines to low-income countries; however, global partners face limitations in meeting vaccine needs. As of 10 June 2021, 2.2 billion doses of COVID-19 vaccine have been administered, but most of these vaccines are from manufacturers based in high-income countries,3 and delays in vaccine availability have been more pronounced in low- and middle-income countries. Additionally, some countries are either not supported through Gavi because they do not meet the eligibility criteria or cannot allocate enough financial resources to purchase vaccines. Timely and wider access to vaccines could be facilitated through local vaccine manufacturing. Countries such as Brazil, Cuba, India, Indonesia and Pakistan have public sector vaccine manufacturing and can therefore make independent decisions on vaccine manufacturing and supply, provision and introduction in their respective health systems. Vaccine development and manufacturing is laborious, requiring not only technological capacity but also financial support from government…more